Open AccessFrom AACR-IASLC Conference on Molecular Origins of Lung Cancer: NSCLC: ALK Inhibitor Produces ‘Dramatic,’ but Not Curative, Responses; Expert Call Now for Routine Genetic Testing
Author(s) -
Rabiya S. Tuma
Publication year - 2010
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000368862.52941.d2
Subject(s) - medicine , lung cancer , oncology , crizotinib , cancer , cancer research , pathology , malignant pleural effusion